Skip to main content
Swedish Orphan Biovitrum logo

Swedish Orphan Biovitrum — Investor Relations & Filings

Ticker · SOBI ISIN · SE0000872095 LEI · 549300124Y3MQI87PT35 ST Manufacturing
Open in API
Filings indexed 892 across all filing types
Latest filing 2022-10-27 Interim / Quarterly Rep…
Country SE Sweden
Listing ST SOBI

About Swedish Orphan Biovitrum

https://www.sobi.com/en

Swedish Orphan Biovitrum (Sobi) is a specialized biopharmaceutical company dedicated to developing and delivering innovative treatments for rare and debilitating diseases. The company's primary focus is on the therapeutic areas of haematology and immunology, with a significant legacy and continued leadership in haemophilia care. Sobi addresses the high unmet medical needs of patients by advancing a pipeline of innovative medicines and working to expand patient access globally. The company's mission is to transform the lives of people affected by rare conditions through dedicated research, development, and global collaboration.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 100% confidence The document provides a detailed financial summary for the third quarter (July-September) and the first nine months (January-September) of 2022. It includes key performance indicators such as revenue, EBITA, EBITA margins, and earnings per share (EPS), along with comparative data from the previous year. Since it contains substantive financial statements and analysis for an interim period rather than just a high-level release or an announcement of a report, it is classified as an Interim/Quarterly Report. 9M 2022
2022-10-27 Swedish
Earnings Release 2022
Earnings Release Classification · 99% confidence The document provides detailed financial results for two distinct periods: 'July – September 2022' (Q3) and 'January – September 2022' (Year-to-Date/Interim period). It includes key metrics like Total revenue, EBITA, and EPS, comparing current figures against prior year periods (Q3 2021 and Jan-Sep 2021). The presence of specific quarterly and year-to-date financial breakdowns, along with an outlook statement ("2022 outlook unchanged"), strongly indicates this is a comprehensive report covering a period shorter than a full year. This aligns perfectly with the definition of an Interim / Quarterly Report (IR). It is not a full Annual Report (10-K) as it focuses on Q3 and YTD figures, nor is it just a brief Earnings Release (ER) as it contains extensive summary tables and detailed segment breakdowns. 9M 2022
2022-10-27 English
Ändring av antalet aktier och röster i Swedish Orphan Biovitrum AB (publ)
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is a press release dated September 30, 2022, titled "Ändring av antalet aktier och röster i Swedish Orphan Biovitrum AB (publ)" (Change in the number of shares and votes in Swedish Orphan Biovitrum AB (publ)). It explicitly states that the total number of shares and votes has changed due to the issuance of C-shares which were converted into common shares to secure incentive program commitments. This directly relates to a change in the company's capital structure (share count). This aligns perfectly with the definition for 'Share Issue/Capital Change' (Code: SHA). It is not a general regulatory filing (RNS) because it fits a specific category, nor is it an announcement of a report (RPA).
2022-09-30 Swedish
New number of shares and votes in Swedish Orphan Biovitrum AB (publ)
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document explicitly announces a change in the 'total number of shares and votes' due to the issuance and subsequent conversion of class C shares into common shares, effective as of September 30, 2022. This directly relates to the company's capital structure and share count. This fits the definition of 'Share Issue/Capital Change' (SHA). It is not a dividend notice (DIV), director dealing (DIRS), or a general earnings release (ER). The final sentence confirms it is regulatory information, but SHA is the most specific category.
2022-09-30 English
Earnings Release 2022
Earnings Release Classification · 99% confidence The document provides detailed financial results for two periods: 'April – juni 2022' (Quarter 2) and 'Januari – juni 2022' (First Half/Interim). It includes key performance indicators like revenue (intäkter), EBITA, EPS, and outlook for the rest of the year. The structure, content (quarterly/half-year figures), and inclusion of management commentary strongly indicate a comprehensive financial report covering a period shorter than a full year. This aligns perfectly with the definition of an Interim / Quarterly Report (IR). It is not a full Annual Report (10-K) as it covers only H1/Q2, nor is it just an Earnings Release (ER) as it contains extensive detail and tables, suggesting a more comprehensive filing than just highlights. H1 2022
2022-07-19 Swedish
Earnings Release 2022
Earnings Release Classification · 99% confidence The document text provides detailed financial highlights for two distinct periods: 'April – June 2022' (Q2) and 'January – June 2022' (H1), along with a '2022 outlook'. It includes key metrics like Total revenue, EBITA, EPS, and segment performance (Haematology, Immunology). This structure, focusing on quarterly and half-year results with forward guidance, is characteristic of an Interim/Quarterly Report (IR) or an Earnings Release (ER). Since the text contains comprehensive segment breakdowns, detailed comparisons (CER, IAC adjustments), and a full financial summary table covering H1 results, it goes beyond the 'key highlights only' scope of a typical Earnings Release (ER). It is a comprehensive report covering a period shorter than a year (half-year results are present). Therefore, it is classified as an Interim / Quarterly Report (IR). The document length is substantial (305k chars), confirming it is the report itself, not just an announcement (RPA/RNS). H1 2022
2022-07-19 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.